简 EN 繁
简 EN 繁

Please enter the information you want to find

Hot key words：
Hyaluronidase xxx
News Center News Center

News Center

2025.12.10

​Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics

View details
​Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics
【News】Bao Pharma's Recombinant Human Hyaluronidase Successfully Registered in the U.S. FDA DMF
2025.05.16

【News】Bao Pharma's Recombinant Human Hyaluronidase Successfully Registered in the U.S. FDA DMF

View details
【News】 Bao Pharma's "KJ103 for Injection" (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase) Receives NMPA Approval for New Indication Clinical Trial
2025.04.29

【News】 Bao Pharma's "KJ103 for Injection" (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase) Receives NMPA Approval for New Indication Clinical Trial

View details
World's First Low-Immunogenic IgG-Degrading Enzyme — Ricefidase Phase III Clinical Trial Officially Launched
2025.04.21

World's First Low-Immunogenic IgG-Degrading Enzyme — Ricefidase Phase III Clinical Trial Officially Launched

View details
[News] BaoPharma's KJ015 Injection (Subcutaneous) Receives Clinical Trial Approval from the NMPA
2025.02.13

[News] BaoPharma's KJ015 Injection (Subcutaneous) Receives Clinical Trial Approval from the NMPA

View details
12345